Want to see APRE full AI Analyst Report?
Top Page
Aprea Therapeutics
(NASDAQ:APRE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.67
▲(5.56% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (zero/minimal revenue, ongoing losses, and continued cash burn), which outweighs the benefit of a debt-free balance sheet. Technicals are broadly neutral but with a weak longer-term trend (below key moving averages and slightly negative MACD) and high volatility (beta ~2.12). Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Low leverage / No debt
Aprea’s near-zero debt profile materially reduces refinancing and interest-rate risk for a clinical-stage biotech with multi-year R&D timelines. This structural strength preserves financial optionality, making future fundraising or partnering less encumbered by fixed obligations.
Negative Factors
Consistent negative cash flow
Repeated negative operating and free cash flow is a structural constraint for a development-stage biotech. Persistent cash burn forces recurring capital raises or partnership compromises, increasing dilution risk and pressuring long-term strategic choices if clinical progress stalls.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / No debt
Aprea’s near-zero debt profile materially reduces refinancing and interest-rate risk for a clinical-stage biotech with multi-year R&D timelines. This structural strength preserves financial optionality, making future fundraising or partnering less encumbered by fixed obligations.
Read all positive factors
Aprea Therapeutics (APRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.56M
Dividend YieldN/A
Average Volume (3M)55.77K
Price to Earnings (P/E)―
Beta (1Y)2.12
Revenue Growth-99.38%
EPS Growth53.42%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.29
Shares Outstanding12,591,136
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.73Price Target Upside492.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07M
Aprea Therapeutics Business Overview & Revenue Model
Company Description
Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company’s pipeline has centered on small-molecule drug candidates intended to target tumor biology (historically inc...
How the Company Makes Money
null...
Aprea Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.50M | 583.23K | 0.00 | 0.00 |
| Gross Profit | -5.43K | 0.00 | -7.86M | 576.18K | -16.40M | -271.68K |
| EBITDA | -12.29M | -12.58M | -12.94M | -14.28M | -37.37M | -36.86M |
| Net Income | -12.31M | -12.60M | -12.96M | -14.29M | -112.66M | -36.54M |
Balance Sheet | ||||||
| Total Assets | 42.29M | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Cash, Cash Equivalents and Short-Term Investments | 41.23M | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 190.47K |
| Total Liabilities | 3.82M | 3.49M | 4.67M | 4.39M | 4.51M | 7.32M |
| Stockholders Equity | 38.47M | 12.44M | 19.31M | 18.26M | 25.64M | 49.51M |
Cash Flow | ||||||
| Free Cash Flow | -12.18M | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Operating Cash Flow | -12.17M | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Investing Cash Flow | -15.75K | 0.00 | -15.48K | -93.09K | 0.00 | 0.00 |
| Financing Cash Flow | 36.89M | 4.64M | 14.82M | 5.14M | 682.97K | 1.75M |
Aprea Therapeutics Technical Analysis
Neutral
0.63
Price Trends
0.71
Negative
0.77
Negative
0.86
Negative
Market Momentum
-0.01
Negative
52.56
Neutral
44.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Neutral. The current price of 0.63 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.71, and below the 200-day MA of 0.86, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.56 is Neutral, neither overbought nor oversold. The STOCH value of 44.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APRE.
Aprea Therapeutics Risk Analysis
Aprea Therapeutics disclosed 79 risk factors in its most recent earnings report. Aprea Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aprea Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $8.56M | -0.53 | -59.54% | ― | -99.38% | 53.42% | |
44 Neutral | $10.84M | -0.59 | -96.39% | ― | ― | 81.87% | |
43 Neutral | $9.98M | -0.29 | -292.33% | ― | ― | 86.17% | |
42 Neutral | $6.62M | -0.17 | -153.80% | ― | ― | 99.50% |
* Healthcare Sector Average
APRE
Aprea Therapeutics
0.68
-0.97
-58.85%
ERNA
Eterna Therapeutics
4.27
-35.98
-89.39%
QNRX
Quoin Pharmaceuticals
5.09
-2.06
-28.81%
NCNA
Nucana
1.59
-2.28
-58.91%
INAB
IN8bio
1.10
-1.29
-53.97%
Aprea Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Aprea Therapeutics advances APR-1051 oncology pipeline progress
Positive
Aug 12, 2026
On August 12, 2026, Aprea Therapeutics reported second-quarter 2026 results and detailed progress across its oncology pipeline, led by WEE1 inhibitor APR-1051. The company is accelerating enrollment in the ACESOT-1051 Phase 1 trial, expanding from...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Aprea Shareholders Approve Directors, Reverse Split Flexibility
Positive
Jun 17, 2026
At its annual meeting of stockholders held on June 16, 2026, Aprea Therapeutics, Inc. reported that a quorum of approximately 66.8% of eligible shares was present and stockholders elected three Class I directors, Marc Duey, Richard Peters and Bern...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.